Feasibility of single-dose neoadjuvant pembrolizumab with subablative radiotherapy in operable breast cancer: a single-centre phase 1b/2 window-of-opportunity trial
Year: 2026
Type: article
Abstract: BACKGROUND: Short preoperative immune induction could inform future breast-cancer trials, but it must not delay surgery. BreastVAX tested whether a single-dose preoperative regimen could be delivered within the planned surgical window while collecting safety and biological data. METHODS: BreastVAX (NCT04454528) was a single-centre, open-label, phase 1b/2 window-of-opportunity trial. Adults with operable invasive breast cancer scheduled for upfront surgery received one 200 mg pembrolizumab infusion alone or with one 7 Gy tumour-directed radiotherapy fraction before or after pembrolizumab. The primary phase 1b endpoint was feasibility, defined as completion of assigned preoperative treatment within 21 days without delaying surgery by more than 14 days. Phase 2 had two descriptive interim reviews. FINDINGS: In phase 1b, all six enrolled participants met the feasibility criterion. Across both phases, all 30 treated participants completed assigned preoperative therapy and underwent surgery without protocol-defined delay; median follow-up was 634 days (IQR 256-1120). Most adverse events were grade 1-2, with no deaths and no treatment-related grade 3 or higher events; the only grade 3 event was a surgical re-excision unrelated to treatment. Pathological and immune-correlative findings were exploratory and showed treatment-associated immune changes, including a neoepitope-reactive T-cell response in one responder. INTERPRETATION: Pembrolizumab, with or without a single subablative tumour-directed radiotherapy fraction, was delivered within the preoperative window without protocol-defined surgical delay. Larger biomarker-informed studies should evaluate sequence prospectively, use endpoints suited to this short regimen, and prespecify harms monitoring. FUNDING: Philanthropic support to JCT and in-kind pembrolizumab supply from Merck Pharmaceuticals.
Source: EBioMedicine
Authors: Julia C. Tchou, Anupma Nayak, Julia Han Noll, He N. Xu, Kevin R. Amses, Sonia Ndeupen, Bing Yi, Jack Kollmar, Evan Smith, Michelle Gelman, Zane Mazur, Neil K. Taunk, Amy S. Clark, Alexander C. Huang, Owen Koucky, Vanessa Gonzalez, Li Sun, Kaitao Li, Paul W. Shafer, Kelsy C. Cotto, Michael J. Malone, Jonathan A. DiRusso, Rong Xu, Christina M. Bailey, Robert Bartoszek, Jennifer L. Hope, Luke Keele, Oluwadamilola M. Fayanju, Angela R. Bradbury, Saveri Bhattacharya, Angela M. DeMichele, Payal D. Shah, Susan M. Domchek, Rachel C. Jankowitz, Hayley M. Knollman, Igor Makhlin, Frederic D. Bushman, Gary M. Freedman, Gaorav Gupta, Andy J. Minn, Joseph A. Fraietta, Andrew J. Rech
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $5,780
OpenAlex ID: W7220744309
